Display options
Cite
Huang S, Sandholm K, Jonsson N, et al. Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clin Kidney J. 2014;8(1):31-7doi: 10.1093/ckj/sfu127.
Huang, S., Sandholm, K., Jonsson, N., Nilsson, A., Wieslander, A., Grundström, G., Hancock, V., & Ekdahl, K. N. (2015). Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clinical kidney journal, 8(1), 31-7. https://doi.org/10.1093/ckj/sfu127
Huang, Shan, et al. "Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood." Clinical kidney journal vol. 8,1 (2015): 31-7. doi: https://doi.org/10.1093/ckj/sfu127
Huang S, Sandholm K, Jonsson N, Nilsson A, Wieslander A, Grundström G, Hancock V, Ekdahl KN. Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood. Clin Kidney J. 2015 Feb;8(1):31-7. doi: 10.1093/ckj/sfu127. Epub 2014 Dec 01. PMID: 25713707; PMCID: PMC4310429.
Copy Download .nbib Format: NLM
Share it on

Clin Kidney J. 2015 Feb;8(1):31-7. doi: 10.1093/ckj/sfu127. Epub 2014 Dec 01.

Low concentrations of citrate reduce complement and granulocyte activation in vitro in human blood.

Clinical kidney journal

Shan Huang, Kerstin Sandholm, Nina Jonsson, Anders Nilsson, Anders Wieslander, Gunilla Grundström, Viktoria Hancock, Kristina N Ekdahl

Affiliations

  1. Linnæus Center for Biomaterials Chemistry , Linnæus University , Kalmar , Sweden.
  2. Linnæus Center for Biomaterials Chemistry , Linnæus University , Kalmar , Sweden ; Department of Immunology, Genetics and Pathology (IGP), Rudbeck Laboratory C5:3 , Uppsala University , Uppsala , Sweden.
  3. Gambro Lundia AB , Lund , Sweden.

PMID: 25713707 PMCID: PMC4310429 DOI: 10.1093/ckj/sfu127

Abstract

BACKGROUND: The use of acetate in haemodialysis fluids may induce negative effects in patients including nausea and increased inflammation. Therefore, haemodialysis fluids where acetate is substituted with citrate have recently been developed. In this study, we investigated the biocompatibility of citrate employing concentrations used in haemodialysis.

METHODS: The effects of citrate and acetate were investigated in human whole blood in vitro under conditions promoting biomaterial-induced activation. Complement activation was measured as generation of C3a, C5a and the sC5b-9 complex, and granulocyte activation as up-regulation of CD11b expression. For the experimental set-up, a mathematical model was created to calculate the concentrations of acetate and citrate attained during haemodialysis.

RESULTS: Citrate reduced granulocyte activation and did not induce higher complement activation compared with acetate at concentrations attained during haemodialysis. Investigating different citrate concentrations clearly showed that citrate is a potent complement inhibitor already at low concentrations, i.e. 0.25 mM, which is comparable with concentrations detected in the blood of patients during dialysis with citrate-containing fluids. Increased citrate concentration up to 6 mM further reduced the activation of C3a, C5a and sC5b-9, as well as the expression of CD11b.

CONCLUSIONS: Our results suggest that citrate is a promising substitute for acetate for a more biocompatible dialysis, most likely resulting in less adverse effects for the patients.

Keywords: acetate; biocompatibility; citrate; complement; haemodialysis

References

  1. Blood Purif. 2012;33(1-3):199-204 - PubMed
  2. Blood Purif. 2013;35(1-3):133-8 - PubMed
  3. Kidney Int. 1982 Mar;21(3):513-8 - PubMed
  4. G Ital Nefrol. 2011 Jul-Aug;28(4):359-68 - PubMed
  5. Crit Care. 2009;13(6):R193 - PubMed
  6. Nephrol Dial Transplant. 2002;17 Suppl 8:10-5 - PubMed
  7. Clin J Am Soc Nephrol. 2009 Sep;4(9):1459-64 - PubMed
  8. Am J Kidney Dis. 2005 Nov;46(5):903-7 - PubMed
  9. Biomaterials. 1999 Apr;20(7):603-11 - PubMed
  10. Kidney Int. 1998 Apr;53(4):1044-51 - PubMed
  11. Scand J Immunol. 1992 Jan;35(1):85-91 - PubMed
  12. Nephrol Dial Transplant. 2006 Jan;21(1):153-9 - PubMed
  13. Blood Purif. 2010;29(2):197-203 - PubMed
  14. Mol Immunol. 2007 Jan;44(1-3):82-94 - PubMed
  15. N Engl J Med. 1983 Feb 3;308(5):258-61 - PubMed
  16. BMC Nephrol. 2009 Mar 05;10:7 - PubMed
  17. Am J Kidney Dis. 2000 Mar;35(3):493-9 - PubMed
  18. Blood Purif. 2012;33(1-3):7-20 - PubMed
  19. Mol Immunol. 2009 Sep;46(14):2753-66 - PubMed
  20. Nephrol Dial Transplant. 2009 Jul;24(7):2244-51 - PubMed
  21. J Am Soc Nephrol. 1997 Sep;8(9):1431-6 - PubMed
  22. Am J Kidney Dis. 1987 Feb;9(2):147-53 - PubMed
  23. J Clin Immunol. 1996 Jul;16(4):222-9 - PubMed
  24. Immunology. 1999 May;97(1):166-72 - PubMed
  25. J Biomed Mater Res A. 2009 Jun 15;89(4):951-9 - PubMed
  26. J Artif Organs. 2011 Jun;14(2):112-9 - PubMed
  27. Scand J Immunol. 1993 Mar;37(3):349-54 - PubMed
  28. Blood Purif. 2012;33(1-3):80-7 - PubMed
  29. Blood Purif. 2012;34(3-4):336-43 - PubMed
  30. Invest Ophthalmol Vis Sci. 1985 Sep;26(9):1257-61 - PubMed
  31. Int J Artif Organs. 2013 Jan;36(1):1-6 - PubMed
  32. Kidney Int. 1999 Oct;56(4):1578-83 - PubMed
  33. Scand J Immunol. 1985 Aug;22(2):197-202 - PubMed
  34. Invest Ophthalmol Vis Sci. 1988 Jun;29(6):869-75 - PubMed
  35. Am J Kidney Dis. 2005 Mar;45(3):557-64 - PubMed
  36. Nephrol Dial Transplant. 2002;17 Suppl 8:16-24 - PubMed
  37. BMC Nephrol. 2013 Oct 09;14:216 - PubMed

Publication Types